Shots:
- Quince Therapeutics has completed enrolment in its P-III (NEAT) trial to assess eDSP (6 infusions once every 21–30 days) vs PBO in Ataxia-Telangiectasia pts (n=105), incl. 83 pts (6-9yrs.) in primary analysis population & 22 pts aged ≥10yrs.
- Trial will assess change from baseline to the last efficacy visit using RmICARS as the 1EP; pts may then enter the NEAT OLE study, subject to completion of treatment, study assessments, & informed consent
- Additionally, the company expects to report topline P-III (NEAT) trial results in Q1’26 & plans to submit an NDA to the US FDA in H2’26, pending positive trial outcomes
Ref: Quince Therapeutics | Image: Quince Therapeutics | Press Release
Related News:- Eli Lilly Receives the Health Canada’s Approval for Omvoh (Mirikizumab) to Treat Crohn’s Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
